Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)Completed
NCT02146378N/AUpdated Feb 3, 2025
Sponsor: Pfizer
Transthyretin Familial Amyloid Polyneuropathy
Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR AmyloidosisRecruiting
NCT04535349NAUpdated Jan 31, 2025
Sponsor: University Hospital, Caen
Amyloidosis Transthyretin
France
A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult VolunteersCompleted
NCT06122194Phase 1Updated Jan 30, 2025
Sponsor: Pfizer
Healthy
Belgium
PhII ICb With/Without Erbitux in MBC PtsActive Not Recruiting
NCT00248287Phase 2Updated Jan 29, 2025
Sponsor: US Oncology Research
Metastatic Breast Cancer
United States
The PROMISE Study: Duavee in Women With DCISCompleted
NCT02694809Phase 2Updated Jan 28, 2025
Sponsor: Northwestern University
Ductal Breast Carcinoma In Situ · Postmenopausal
United States
PsoBest - The German Psoriasis RegistryRecruiting
NCT01848028N/AUpdated Jan 27, 2025
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Psoriasis · Psoriatic-arthritis
Germany
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesCompleted
NCT01254864Phase 2Updated Jan 27, 2025
Sponsor: M.D. Anderson Cancer Center
Prostate Cancer
United States
A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in ChinaCompleted
NCT05732428Phase 1Updated Jan 27, 2025
Sponsor: Pfizer
Breast Cancer
China
A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy AdultsCompleted
NCT06693518Phase 1Updated Jan 24, 2025
Sponsor: Pfizer
SARS-CoV-2 Infections
Belgium
Sickle-cell Disease Registry of the GPOHRecruiting
NCT03327428N/AUpdated Jan 24, 2025
Sponsor: University Hospital Heidelberg
Sickle Cell Disease
Germany
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)Terminated
NCT01121588Phase 1Updated Jan 23, 2025
Sponsor: Pfizer
Neoplasms Malignant
United States, China, Italy, Japan, Russia +2 more
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerCompleted
NCT04703920Phase 1Updated Jan 23, 2025
Sponsor: University of Michigan Rogel Cancer Center
Metastatic Breast Cancer · Metastatic Castration-resistant Prostate Cancer · Metastatic Ovarian Carcinoma · Metastic or Unresectable Pancreatic Adenocarcinoma
United States
A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.Completed
NCT06392230Phase 1Updated Jan 23, 2025
Sponsor: Pfizer
Healthy Participants
Netherlands
A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called MidazolamCompleted
NCT06256510Phase 1Updated Jan 21, 2025
Sponsor: Pfizer
Healthy Participants
Belgium
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).Terminated
NCT05534789N/AUpdated Jan 20, 2025
Sponsor: Pfizer
Carcinoma, Renal Cell
United States
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or ObesityCompleted
NCT06568731Phase 1Updated Jan 20, 2025
Sponsor: Pfizer
Obesity
United States
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.Terminated
NCT04171141Phase 1Updated Jan 16, 2025
Sponsor: Pfizer
Gastrointestinal Tumors · Colorectal Adenocarcinomas · Gastric Adenocarcinomas · Esophageal Adenocarcinomas
United States, Australia, Japan
Incidence of Melanoma and Non-melanoma Skin Cancer in People With VitiligoCompleted
NCT04969419N/AUpdated Jan 14, 2025
Sponsor: Momentum Data
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer · Squamous Cell Carcinoma
United Kingdom
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity RangeTerminated
NCT05671653Phase 1Updated Jan 14, 2025
Sponsor: Pfizer
Obesity
United States
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsActive Not Recruiting
NCT03709680Phase 2Updated Jan 14, 2025
Sponsor: Pfizer
Ewing Sarcoma · Solid Tumors · Rhabdoid Tumor · Rhabdomyosarcoma
United States, Brazil, Canada, Czechia, France +9 more
Reliability of Rimegepant or Triptans for the Acute Treatment of MigraineCompleted
NCT06412965N/AUpdated Jan 13, 2025
Sponsor: Pfizer
Migraine Disorders
United States
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid TumorsTerminated
NCT03854227Phase 1Updated Jan 13, 2025
Sponsor: Pfizer
Advanced Solid Tumors · Metastatic Solid Tumors
United States
A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver FunctionCompleted
NCT06340347Phase 1Updated Jan 10, 2025
Sponsor: Pfizer
Liver Diseases
United States
StrataPATH™ (Precision Indications for Approved Therapies)Terminated
NCT05097599Phase 2Updated Jan 8, 2025
Sponsor: Strata Oncology
Cancer · Advanced Solid Tumor
United States
A GBT021601 ADME Microtracer Study in Healthy VolunteersCompleted
NCT05718687Phase 1Updated Jan 8, 2025
Sponsor: Pfizer
Sickle Cell Disease
Netherlands

Previous page Next page